Long-Term Debt: The sum of all long term debt fields.
BioCryst Pharmaceuticals, Inc. (BCRX) had Long-Term Debt of $803.55M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$156.41M |
|
$-721.81M |
|
$5.38M |
|
$151.04M |
|
$858.01M |
|
$-701.60M |
|
$-19.21M |
|
$-720.81M |
|
$-720.81M |
|
$-721.81M |
|
$-721.81M |
|
$-721.81M |
|
$-721.81M |
|
$-701.60M |
|
$-700.14M |
|
242.26M |
|
242.26M |
|
$-2.98 |
|
$-2.98 |
|
| Balance Sheet Financials | |
$373.62M |
|
$9.37M |
|
$91.43M |
|
$465.05M |
|
$195.39M |
|
|
Long-Term Debt |
$803.55M |
$823.50M |
|
$1.02B |
|
$-553.84M |
|
$-553.84M |
|
$-553.84M |
|
254.01M |
|
| Cash Flow Statement Financials | |
$-61.79M |
|
$-268.65M |
|
$412.55M |
|
$91.34M |
|
$173.38M |
|
$82.04M |
|
$16.03M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.91 |
|
-- |
|
-- |
|
3.22 |
|
-1.56 |
|
96.56% |
|
-448.55% |
|
-448.55% |
|
-- |
|
-460.84% |
|
-461.48% |
|
$-62.19M |
|
-- |
|
-- |
|
-- |
|
0.34 |
|
0.90 |
|
1.43 |
|
62.88 |
|
130.33% |
|
130.33% |
|
-155.21% |
|
-289.06% |
|
$-2.18 |
|
$-0.26 |
|
$-0.26 |
|